Protara Therapeutics Announces Dosing of First Patient in Phase 1b/2 ADVANCED-2 Trial of TARA-002 in NMIBC Patients with High Grade Carcinoma in Situ
September 20, 2023 08:30 ET
|
Protara Therapeutics
NEW YORK, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases,...
Protara Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
September 05, 2023 07:30 ET
|
Protara Therapeutics
NEW YORK, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases,...
Protara Therapeutics Announces Second Quarter 2023 Financial Results and Business Update
August 03, 2023 08:00 ET
|
Protara Therapeutics
Dosing is progressing on schedule in ADVANCED-1EXP trial evaluating TARA-002 in NMIBC patients with CIS; preliminary results expected in 1H24Company plans to commence dosing in ADVANCED-2 trial...
Protara Therapeutics Announces Dosing of First Patients in Phase 1b ADVANCED-1EXP Trial of TARA-002 in NMIBC Patients with Carcinoma in Situ
May 15, 2023 08:00 ET
|
Protara Therapeutics
Dosing of first patients follows recent presentation of positive preliminary data from Phase 1a dose escalation portion of ADVANCED-1 trialCompany advancing NMIBC clinical development program, with...
Protara Therapeutics Announces First Quarter 2023 Financial Results and Business Update
May 04, 2023 08:00 ET
|
Protara Therapeutics
Favorable tolerability and anti-tumor activity observed in NMIBC patients treated with TARA-002 in ADVANCED-1 trialCompany plans to initiate ADVANCED-2 trial in BCG-naïve CIS patients and...
Protara Therapeutics Receives Regulatory Clearance from FDA to Commence Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations
May 02, 2023 08:00 ET
|
Protara Therapeutics
STARBORN-1 trial leverages data from TARA-002 predecessor therapy OK-432, which is approved and has treated thousands of pediatric patients with Lymphatic Malformations in Japan and Taiwan as well as...
Protara Therapeutics Announces Positive Preliminary Data from ADVANCED-1 Phase 1a Dose Escalation Trial of TARA-002 in NMIBC Supporting Advancement into Phase 2 Clinical Development
April 28, 2023 08:00 ET
|
Protara Therapeutics
Favorable tolerability observed in patients with NMIBC treated with TARA-002 in ADVANCED-1 trialAnti-tumor activity was observed in all three evaluable patients with CIS, including one heavily...
Protara Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
March 08, 2023 08:00 ET
|
Protara Therapeutics
- Data from Phase 1a Portion of ADVANCED-1 Trial of TARA-002 for the Treatment of Non-Muscle Invasive Bladder Cancer Expected in 2Q23 – - Start up Activities for Phase 2 Trial of TARA-002 in...
Protara Therapeutics to Participate in Upcoming Investor Conferences
March 01, 2023 08:00 ET
|
Protara Therapeutics
NEW YORK, March 01, 2023 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases,...
Protara Therapeutics to Present at the Guggenheim Healthcare Talks Oncology Day
February 02, 2023 08:00 ET
|
Protara Therapeutics
NEW YORK, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases,...